MIN-102 study

Following the MIN-102 study in males with adrenomyeloneuropathy, Minoryx Therapeutics are now sponsoring a trial to determine if MIN-102 may provide further protection against cerebral ALD prior to transplant. The study is being conducted in Europe (namely Germany and Spain) and is for patients with early stage cerebral lesions only.

Click the image to download the PDF